207 related articles for article (PubMed ID: 21175232)
1. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
Cravo M; Silva R; Serrano M
BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
[TBL] [Abstract][Full Text] [Related]
2. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
3. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
[TBL] [Abstract][Full Text] [Related]
5. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
6. [Adalimumab in Crohn's disease - data from real life].
López San Román A; Van Domselaar M; Garrido E
Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
9. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Barthel HR; Gille T; Halbsguth A; Kramer M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
[No Abstract] [Full Text] [Related]
10. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.
Stallmach A; Giese T; Schmidt C; Meuer SC; Zeuzem SS
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):627-30. PubMed ID: 15167167
[TBL] [Abstract][Full Text] [Related]
11. What next after infliximab?
Baidoo L; Lichtenstein GR
Am J Gastroenterol; 2005 Jan; 100(1):80-3. PubMed ID: 15654785
[TBL] [Abstract][Full Text] [Related]
12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
15. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
16. A pilot study of adalimumab in infliximab-allergic patients.
Youdim A; Vasiliauskas EA; Targan SR; Papadakis KA; Ippoliti A; Dubinsky MC; Lechago J; Paavola J; Loane J; Lee SK; Gaiennie J; Smith K; Do J; Abreu MT
Inflamm Bowel Dis; 2004 Jul; 10(4):333-8. PubMed ID: 15475739
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease.
Mian S; Baron H
J Pediatr Gastroenterol Nutr; 2005 Sep; 41(3):357-9. PubMed ID: 16131995
[No Abstract] [Full Text] [Related]
18. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
Parkes GC; Hedin CRH
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):489-491. PubMed ID: 38640938
[No Abstract] [Full Text] [Related]
19. The use of adalimumab in the management of refractory Crohn's disease.
Ho GT; Smith L; Aitken S; Lee HM; Ting T; Fennell J; Lees CW; Palmer KR; Penman ID; Shand AG; Arnott ID; Satsangi J
Aliment Pharmacol Ther; 2008 Feb; 27(4):308-15. PubMed ID: 18081730
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab: in Crohn's disease.
Plosker GL; Lyseng-Williamson KA
BioDrugs; 2007; 21(2):125-32; discussion 133-4. PubMed ID: 17402796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
